Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?

Circ Res. 2015 Jul 17;117(3):229-33. doi: 10.1161/CIRCRESAHA.117.306306.


Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

Keywords: cell- and tissue-based therapy; chronic heart failure; clinical trial; heart disease; mesenchymal stem cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allografts
  • Animals
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Endpoint Determination
  • Heart Failure / therapy*
  • Humans
  • Mesenchymal Stem Cell Transplantation / adverse effects
  • Mesenchymal Stem Cell Transplantation / methods
  • Mesenchymal Stem Cell Transplantation / trends*
  • Multicenter Studies as Topic
  • Myocardial Infarction / therapy*
  • Myocardial Ischemia / therapy
  • Pilot Projects
  • Regenerative Medicine / methods
  • Regenerative Medicine / trends*
  • Transplantation, Autologous
  • Treatment Outcome